Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Oncolytic adenovirus coding for bispecific T cell engager against human MUC-1 potentiates T cell response against solid tumors.
Basnet S, Santos JM, Quixabeira DCA, Clubb JHA, Grönberg-Vähä-Koskela SAM, Arias V, Pakola S, Kudling TV, Heiniö C, Havunen R, Cervera-Carrascon V, Sorsa S, Anttila M, Kanerva A, Hemminki A. Basnet S, et al. Among authors: havunen r. Mol Ther Oncolytics. 2022 Dec 28;28:59-73. doi: 10.1016/j.omto.2022.12.007. eCollection 2023 Mar 16. Mol Ther Oncolytics. 2022. PMID: 36699617 Free PMC article.
Adenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma.
Siurala M, Havunen R, Saha D, Lumen D, Airaksinen AJ, Tähtinen S, Cervera-Carrascon V, Bramante S, Parviainen S, Vähä-Koskela M, Kanerva A, Hemminki A. Siurala M, et al. Among authors: havunen r. Mol Ther. 2016 Aug;24(8):1435-43. doi: 10.1038/mt.2016.137. Epub 2016 Jun 30. Mol Ther. 2016. PMID: 27357626 Free PMC article.
Syngeneic syrian hamster tumors feature tumor-infiltrating lymphocytes allowing adoptive cell therapy enhanced by oncolytic adenovirus in a replication permissive setting.
Siurala M, Vähä-Koskela M, Havunen R, Tähtinen S, Bramante S, Parviainen S, Mathis JM, Kanerva A, Hemminki A. Siurala M, et al. Among authors: havunen r. Oncoimmunology. 2016 Feb 18;5(5):e1136046. doi: 10.1080/2162402X.2015.1136046. eCollection 2016 May. Oncoimmunology. 2016. PMID: 27467954 Free PMC article.
Corrigendum to "Adenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma".
Siurala M, Havunen R, Saha D, Lumen D, Airaksinen AJ, Tähtinen S, Cervera-Carrascon V, Bramante S, Parviainen S, Vähä-Koskela M, Kanerva A, Hemminki A. Siurala M, et al. Among authors: havunen r. Mol Ther. 2016 Nov;24(11):2033. doi: 10.1038/mt.2016.196. Mol Ther. 2016. PMID: 27916990 Free PMC article. No abstract available.
Intravenously usable fully serotype 3 oncolytic adenovirus coding for CD40L as an enabler of dendritic cell therapy.
Zafar S, Parviainen S, Siurala M, Hemminki O, Havunen R, Tähtinen S, Bramante S, Vassilev L, Wang H, Lieber A, Hemmi S, de Gruijl T, Kanerva A, Hemminki A. Zafar S, et al. Among authors: havunen r. Oncoimmunology. 2016 Dec 7;6(2):e1265717. doi: 10.1080/2162402X.2016.1265717. eCollection 2017. Oncoimmunology. 2016. PMID: 28344872 Free PMC article.
Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy.
Havunen R, Siurala M, Sorsa S, Grönberg-Vähä-Koskela S, Behr M, Tähtinen S, Santos JM, Karell P, Rusanen J, Nettelbeck DM, Ehrhardt A, Kanerva A, Hemminki A. Havunen R, et al. Mol Ther Oncolytics. 2016 Dec 31;4:77-86. doi: 10.1016/j.omto.2016.12.004. eCollection 2017 Mar 17. Mol Ther Oncolytics. 2016. PMID: 28345026 Free PMC article.
Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.
Watanabe K, Luo Y, Da T, Guedan S, Ruella M, Scholler J, Keith B, Young RM, Engels B, Sorsa S, Siurala M, Havunen R, Tähtinen S, Hemminki A, June CH. Watanabe K, et al. Among authors: havunen r. JCI Insight. 2018 Apr 5;3(7):e99573. doi: 10.1172/jci.insight.99573. eCollection 2018 Apr 5. JCI Insight. 2018. PMID: 29618658 Free PMC article.
39 results